|
OPEN ACCESS PLUS
Accepted articles are published online for free open access for all to view. Open access publishing provides the maximum dissemination of the article to the largest audience. Authors must pay for this service. All corresponding authors will be asked to indicate whether or not they wish to pay to have their paper made freely available on publication. If authors do not select the Open Access option, then their article will be published with standard subscription-based access at no charge.
Authors who opt for Open Access Plus may also self-archive publishers postprints. Bentham Science is compliant with the open access policy for the MRC, Cancer Research UK, NIH, and many other funders. For details, refer to http://www.benthamscience.com/permission.php or email to; openaccess@benthamscience.org.
Contents
Pp. 201 - 206
Tatsuki Sugiyama and Takashi Nagasawa
[Open Access Plus] |
|
In mammals, hematopoietic stem cells (HSCs), which give rise to all blood cells and their progenies, including immune cells are controlled by special microenvironments, termed niches in the bone marrow during homeostasis and infection. However, the identity, nature and function of these niches remain unclear. It has been reported that HSCs are in contact with osteoblasts lining the bone surface and osteoblasts act as niches for HSCs (termed endosteal niche). However, recent studies suggest that only a small number of HSCs reside in the endosteal niche. In contrast, many HSCs are shown to be in contact with endothelial cells in the marrow. In addition, recent studies suggest that primitive mesenchymal cells, including CXCL12-abundant reticular (CAR) cells and Nestin-expressing cells, which have the ability to differentiate into adipocytes as well as osteoblasts act as niches for HSCs. Here we review candidate niches for HSCs in the bone marrow controlling hematopoiesis and chronic inflammation.
|
Pp. 164 - 170
Ari Togashi, Sanae Saito, Fumio Kaneko, Koichiro Nakamura and Noritaka Oyama
[Open Access Plus] |
|
There may be some difficulties to differentiate Behcets disease (BD), recurrent aphthosis (RA), and herpetic aphthous ulceration, from other mimicking oral disorders. Despite of unexpected sensitivity and responsiveness, the skin pathergy test regarding a non-specific hypersensitivity has long been thought as one of auxiliary diagnostic benefits for BD. To determine the potential usefulness and disease specificity of the prick reaction with saliva, a skin prick test with neat and filter-sterilized saliva was performed on the forearm skin of 26 individuals; 10 patients with BD (8 incomplete type without uveitis, 1 complete type, and 1 neurological type), 5 with RA, 3 with herpetic oral aphthosis, 2 with erythema nodosum alone, and 6 healthy controls. We assessed the skin reaction at 48 hours after pricking, and the pricked skin lesions were biopsied and analyzed immunohistologically. Nine of 10 BD patients (90 %) exhibited an indurative erythema at the skin site pricked with self-saliva, whereas 3 of 5 RA patients (60%) were relatively weak reaction. Pricking with filter-sterilized saliva failed to recapitulate any of positive skin reactions, albeit a faint erythematous dot appeared in a few BD patients, implicating the involvement of causative microorganism(s) in oral bacterial flora. Culture of saliva from 3 randomly chosen BD patients revealed numerous streptococcal colonies on Mitis-Salivarius agar. Histology of the pricked skin sites showed perivasucular inflammatory infiltrates, composed of CD4+ T cells and CD68+ monocyte/macrophage lineage, a feature consistent with a delayed type hypersensitive reaction. Our results suggested that skin prick test using self-saliva (a new diagnostic pathergy) can be a simple and valuable in vivo diagnostic approach for differentiating BD and RA from other mimicking mucocutaneous diseases. The positive skin prick may be triggered by resident intra-oral microflora, particularly streptococci, and may in part address the underlying immunopathology in BD.
|
Pp. 110 - 123
Robert E. Newman, Dana Yoo, Michelle A. LeRoux and Alla Danilkovitch-Miagkova
[Open Access Plus] |
|
Human mesenchymal stem cells (hMSCs) are rare progenitor cells present in adult bone marrow that have the capacity to differentiate into a variety of tissue types, including bone, cartilage, tendon, fat, and muscle. In addition to multilineage differentiation capacity, MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component. The availability of bone marrow and the ability to isolate and expand hMSCs ex vivo make these cells an attractive candidate for drug development. The low immunogenicity of these cells suggests that hMSCs can be transplanted universally without matching between donors and recipients. MSCs universality, along with the ability to manufacture and store these cells long-term, present a unique opportunity to produce an “off-the-shelf” cellular drug ready for treatment of diseases in acute settings. Accumulated animal and human data support MSC therapeutic potential for inflammatory diseases. Several phase III clinical trials for treatment of acute Graft Versus Host Disease (GVHD) and Crohns disease are currently in progress. The current understanding of cellular and molecular targets underlying the mechanisms of MSCs action in inflammatory settings as well as clinical experience with hMSCs is summarized in this review.
|
Pp. 91 - 106
John F. Parkinson
[Open Access Plus] |
|
Lipoxin A4 (LXA4) and lipoxin B4 (LXB4) were first identified in 1984 by Serhan and colleagues as 5- and 15- lipoxygenase interaction products of activated leukocytes. Endogenous transcellular biosynthesis of LXA4 and LXB4 occurs via interaction of leukocytes with epithelium, endothelium or platelets. Acetylation of cyclooxygenase-2 (COX-2) by aspirin can trigger 15-epi-LXA4 (ATL) biosynthesis. Elucidating the pharmacological actions of lipoxins and ATL was facilitated by total synthesis of LXA4 in 1988 by Nicolaou and colleagues. In 1994, Fiore and colleagues used [3H]-LXA4 to identify the cDNA for a human G-protein-coupled, high affinity LXA4 and ATL receptor (ALX-R/FPRL-1), providing the first hints for the molecular basis of lipoxin actions. The recognition that lipoxins and ATL undergo rapid, prostaglandin dehydrogenase (PGDH)-mediated metabolic inactivation led do the design and synthesis of first-generation PGDH-resistant LXA4, LXB4 and ATL analogs in 1995-1998 by Serhan, Petasis and colleagues. These relatively stable pharmacological agents, together with myeloid-specific ALX-R-expressing transgenic mice, have provided powerful tools to explore lipoxin functions in vivo. Here we briefly review the substantial body of evidence supporting the lipoxin→ ALX-R pathway as a novel and potent mechanism for preventing/resolving acute inflammation. Emphasis will also be placed on recent findings that lipoxins play new roles in "immunomodulation" via regulation of macrophage, dendritic cell, and T-lymphocyte effector functions in the setting of polarized T-helper cell responses (Th1 and Th2). These studies suggest roles for lipoxins as novel regulators of allergy and adaptive immunity and that lipoxins may have therapeutic potential in chronic immune disorders.
|
|
